RTI Surgical

RTI Surgical is an operating company, not an investment firm, so it does not deploy third-party capital. Strategic decisions around capital allocation, M&A, and product-line investments sit with the board of directors and the executive leadership team, led by President and CEO Olivier Visa since December 2020. The firm is privately held, and the composition of its controlling ownership is not publicly detailed.

RTI sources donated human tissue through a network of accredited tissue recovery agencies and hospital partners in the United States. The firm operates under FDA oversight as a registered human-cell-and-tissue establishment and subjects every donor to rigorous medical-social screening and serological testing consistent with American Association of Tissue Banks standards. Because donor tissue supply depends on altruistic donation, not commercial procurement, RTI's access to tissue is a function of its relationships with organ procurement organizations and its standing with the transplantation community.

RTI Surgical is currently a privately held company. It traded on Nasdaq under the ticker RTIX from its IPO in 2000 until its take-private, though the firm has not disclosed the exact timing or structure of that delisting in its public-facing materials.

RTI divested its OEM metals division to Montagu Private Equity in July 2020 for $480 million in order to become a pure-play biologics and regenerative medicine company. The sale allowed management to concentrate capital and operational focus on higher-margin allograft and xenograft product lines in spine, sports medicine, and soft-tissue reconstruction, while shedding a contract-manufacturing business that served competing orthopedic implant firms.

RTI invests in surgeon education and training as a core commercial function, maintaining a dedicated processing and education center at its Freiberg, Germany location. The firm's product-launch strategy, visible in the 2024 NeuAlign rollout, typically includes cadaveric lab courses, procedural wet labs, and direct surgeon-proctoring programs. The company views education as an embedded cost of market development rather than a standalone profit center.